Virpax® Pharmaceuticals to Present at 2024 BIO Convention

Virpax Pharmaceuticals, Inc., a company dedicated to creating non-addictive therapies for pain management, post-traumatic stress disorder (PTSD), central nervous system (CNS) disorders, and viral protection, has announced its participation in the upcoming Bio International Convention in San Diego. The event will take place on Monday, June 3rd, at 4:00 p.m. PT, in Theater 3. Gerald W. Bruce, the CEO of Virpax, will present the company's latest developments and strategies during this session.

During the convention, Mr. Bruce and his team will also be available for meetings from June 3rd to June 5th. Interested parties can schedule a meeting through the BIO International meeting platform or by contacting betsy.brod@affinitygrowth.com.

Virpax Pharmaceuticals is focusing on developing innovative, non-addictive pain management solutions using proprietary drug delivery technologies. The company is in the process of seeking FDA approval for two prescription drugs that utilize distinct patented delivery methods. The first, Probudur™, is a liposomal bupivacaine injection designed for managing post-operative pain. The second, Envelta™, is an intranasal formulation of molecular envelope enkephalin intended for treating severe pain, including pain experienced by cancer patients.

Additionally, Virpax is working on NobrXiol™, another intranasal product using the company’s Molecular Envelope Technology (MET). This product aims to deliver pharmaceutical-grade cannabidiol (CBD) for treating rare pediatric epilepsy. The company has established competitive cooperative research and development agreements (CRADAs) for two of its prescription drugs, collaborating with the National Institutes of Health (NIH) and the Department of Defense (DOD).

Apart from their prescription products, Virpax is also developing two nonprescription candidates. AnQlar is an antiviral product designed to inhibit the replication of viruses, including influenza and SARS-CoV-2. The second nonprescription candidate, Epoladerm™, is a topical diclofenac spray film meant to manage osteoarthritis-related pain.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!